Literature DB >> 142429

Regulatory dysfunction in leukotaxis.

P A Ward, K J Johnson, D L Kreutzer.   

Abstract

The chemotactic factor inactivator (CFI) in human serum appears to have important regulatory function in the inflammatory response. In humans with elevated serum levels of CFI, defective mobilization of leukocytes in vivo has been noted, both in skin windows and in skin testing with various antigens. In experimental immune complex-induced acute inflammatory reactions in rat skin and lung, purified human CFI at very low doses has potent antiinflammatory effects and is able to suppress permeability changes, neutrophil infiltration, and hemorrhage, all of which are dependent initially on the role of leukotactic mediators.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 142429      PMCID: PMC2032379     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  14 in total

1.  Defective leukotaxis in patients with lepromatous leprosy.

Authors:  P A Ward; S Goralnick; W E Bullock
Journal:  J Lab Clin Med       Date:  1976-06

2.  Quantitative and qualitative studies of the local cellular exudative response in leprosy.

Authors:  W E Bullock; M F Ho; M J Chen
Journal:  J Reticuloendothel Soc       Date:  1974-11

3.  Biologic role of complement products. Complement-derived leukotactic activity extractable from lesions of immunologic vasculitis.

Authors:  P A Ward; J H Hill
Journal:  J Immunol       Date:  1972-05       Impact factor: 5.422

4.  Defective regulation of inflammatory mediators in Hodgkin's disease. Supernormal levels of chemotactic-factor inactivator.

Authors:  P A Ward; J L Berenberg
Journal:  N Engl J Med       Date:  1974-01-10       Impact factor: 91.245

5.  Two distinct chemotactic factor inactivators in human serum.

Authors:  G Till; P A Ward
Journal:  J Immunol       Date:  1975-02       Impact factor: 5.422

6.  Antileukotactic properties of tumor cells.

Authors:  J P Brozna; P A Ward
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

7.  Defective regulation of chemotaxis in cirrhosis.

Authors:  E C Maderazo; P A Ward; R Quintiliani
Journal:  J Lab Clin Med       Date:  1975-04

8.  Chemotactic factor inactivator in normal human serum.

Authors:  J L Berenberg; P A Ward
Journal:  J Clin Invest       Date:  1973-05       Impact factor: 14.808

9.  Suppression of immune complex-induced inflammation by the chemotactic factor inactivator.

Authors:  K J Johnson; T P Anderson; P A Ward
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

10.  Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase.

Authors:  V A Bokisch; H J Müller-Eberhard
Journal:  J Clin Invest       Date:  1970-12       Impact factor: 14.808

View more
  3 in total

1.  What are the molecular characteristics of the neutrophil receptor for chemotactic formylated peptides?

Authors:  R Nairn; R H Smith; C S Brown; W A Marasco
Journal:  Surv Immunol Res       Date:  1985

2.  Alterations in activities of anaphylatoxin inactivator and chemotactic factor inactivator during hemodialysis.

Authors:  J R McCormick; D L Kreutzer; H J Keating; J Hupp; A Despins; M Moore
Journal:  Am J Pathol       Date:  1982-12       Impact factor: 4.307

3.  Directed migration of circulating polymorphonuclear leucocytes in patients with rheumatoid arthritis: a defect in the plasma.

Authors:  J R Walker; D W James; M J Smith
Journal:  Ann Rheum Dis       Date:  1979-06       Impact factor: 19.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.